Replies to post #4329 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Polly

It is my understanding that the HMO's are rejecting Gilenya reimbursement until the patient has failed one or two other drugs first.

The fear isn't cost as much as the unknown long term side effects.

I think sales were $79mil for the 2nd qtr versus $59 for the 1st qtr.